CroíValve
Manufacturing · Ireland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
117-125 Liffey Trust Enterprise Ctr Unit...Phone Number
+35312552139Website
www.croivalve.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About CroíValve
CroíValve is dedicated to improving the lives of patients suffering from tricuspid regurgitation through its innovative DUO System, a minimally invasive heart valve device. The company aims to address the underdiagnosis and undertreatment of this common heart condition, which affects over millions of people in the US and Europe. The DUO System is designed to assist the native tricuspid valve, preserving anatomy and enhancing heart function. Currently, the DUO System is under clinical investigation and is not yet commercially available.Explore more
CroíValve Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CroíValve your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if CroíValve is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if CroíValve had a recent Job posting/layoffs
Check if CroíValve has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once CroíValve has new funding data
Product Launch: Get notified when CroíValve launches new products
Earning: See what the market has to say on CroíValve recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at CroíValve
CroíValve, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
CroíValve is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CroíValve is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CroíValve.
CroíValve financials insights
Gather financial insights about CroíValve, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Multiple Rounds
$12.8M
2022
Unspecified
$9M
2026
Series B
$36M
Grant
$7M
CroíValve Tech Stack
A closer look at the technologies used by CroíValve
See more technologies
Most Recent Scoops
Funding
Funding
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Hiring Plans
CroíValve News & Media
CroíValve Announces First Implant of a Novel Minimally Invasive Device for Tricuspid Regurgitation in US Early Feasibility Study
DUBLIN--(BUSINESS WIRE)--CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment of severe+ tricuspid regurgitation (TR), announced the first patient treated with the DUO™ System as part of the TANDEM II Early Feasibility Study in the U.S. The DUO™ System is a transcatheter valve that works in tandem with the native tricuspid valve to restore valve function while preserving the native valve apparatus. The TANDEM II StudyCroíValve Announces $16 Million Equity Financing to Fund US Early Feasibility Study of Novel Transcatheter Tricuspid Device
DUBLIN--(BUSINESS WIRE)--CroíValve Announces $16 Million Equity Financing to Fund US Early Feasibility Study of Novel Transcatheter Tricuspid Device.Positive Six-Month Results from CroíValve’s TANDEM I Study to Treat Tricuspid Regurgitation Presented at New York Valves 2024
DUBLIN--(BUSINESS WIRE)--Favorable patient outcomes from the TANDEM I first-in-human clinical trial of the CroíValve DUO™ System for the percutaneous treatment of tricuspid regurgitation (TR) were presented today by Professor Wojciech Wojakowski at the New York Valves 2024 scientific conference. The DUO System is a novel transcatheter coaptation valve that works in tandem with the native tricuspid valve to restore valve function, using an anchor system which leaves the right heart and native va
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CroíValve
Sign Up For FreeTo access detailed company insights
CroíValve is dedicated to improving the lives of patients suffering from tricuspid regurgitation through its innovative DUO System, a minimally invasive heart valve device. The company aims to address the underdiagnosis and undertreatment of this common heart condition, which affects over millions of people in the US and Europe. The DUO System is d... Read More
